Arrowstreet Capital
VKTX icon

Arrowstreet Capital’s Viking Therapeutics VKTX Stock Holding History

Arrowstreet Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,300
Closed -$92K – 2556
2020
Q4 		$92K Buy
+16,300
New +$98.7K ﹤0.01% 2229
2018
Q3 		– Sell
-31,807
Closed -$302K – 1269
2018
Q2 		$302K Buy
+31,807
New +$212K ﹤0.01% 971

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arrowstreet Capital's VKTX Position: Q1 2021 in Review

Arrowstreet Capital sold out of Viking Therapeutics (VKTX) in Q1 2021, closing a stake of 16,300 shares — an estimated $92K sold.

Arrowstreet Capital first reported a position in VKTX in Q2 2018 and held it in 2 quarters. The position peaked at $302K in Q2 2018. 144 funds tracked by Wall St. Rank hold VKTX as of Q1 2021.

  • Arrowstreet Capital reported no remaining Viking Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 16,300 Viking Therapeutics shares in Q1 2021, an estimated $92K.
  • Arrowstreet Capital first reported a position in Viking Therapeutics in Q2 2018 and held it in 2 quarters.
  • Arrowstreet Capital's Viking Therapeutics position peaked at $302K in Q2 2018.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.